Literature DB >> 12692591

'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo.

D Bonci1, A Cittadini, M V G Latronico, U Borello, J K Aycock, A Drusco, A Innocenzi, A Follenzi, M Lavitrano, M G Monti, J Ross, L Naldini, C Peschle, G Cossu, G Condorelli.   

Abstract

Efficient gene transduction in cardiomyocytes is a task that can be accomplished only by viral vectors. Up to now, the most commonly used vectors for this purpose have been adenoviral-derived ones. Recently, it has been demonstrated that lentiviral vectors can transduce growth-arrested cells, such as hematopoietic stem cells. Moreover, a modified form of lentiviral vector (the 'advanced' generation), containing an mRNA-stabilizer sequence and a nuclear import sequence, has been shown to significantly improve gene transduction in growth-arrested cells as compared to the third-generation vector. Therefore, we tested whether the 'advanced' generation lentivirus is capable of infecting and transducing cardiomyocytes both in vitro and in vivo, comparing efficacy in vitro against the third-generation of the same vector. Here we report that 'advanced' generation lentiviral vectors infected most (>80%) cardiomyocytes in culture, as demonstrated by immunofluorescence and FACS analyses: in contrast the percentage of cardiomyocytes infected by third-generation lentivirus was three- to four-fold lower. Moreover, 'advanced' generation lentivirus was also capable of infecting and inducing stable gene expression in adult myocardium in vivo. Thus, 'advanced' generation lentiviral vectors can be used for both in vitro and in vivo gene expression studies in the cardiomyocyte.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692591     DOI: 10.1038/sj.gt.3301936

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  39 in total

1.  Efficient reprogramming of adult neural stem cells to monocytes by ectopic expression of a single gene.

Authors:  Magda Forsberg; Marie Carlén; Konstantinos Meletis; Maggie S Y Yeung; Fanie Barnabé-Heider; Mats A A Persson; Johan Aarum; Jonas Frisén
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-30       Impact factor: 11.205

2.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

Authors:  Nadia Felli; Laura Fontana; Elvira Pelosi; Rosanna Botta; Desirée Bonci; Francesco Facchiano; Francesca Liuzzi; Valentina Lulli; Ornella Morsilli; Simona Santoro; Mauro Valtieri; George Adrian Calin; Chang-Gong Liu; Antonio Sorrentino; Carlo M Croce; Cesare Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

Review 3.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 4.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

5.  The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Authors:  A Rosa; M Ballarino; A Sorrentino; O Sthandier; F G De Angelis; M Marchioni; B Masella; A Guarini; A Fatica; C Peschle; I Bozzoni
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

Review 6.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

Review 7.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 8.  Methods in cardiomyocyte isolation, culture, and gene transfer.

Authors:  William E Louch; Katherine A Sheehan; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-06-24       Impact factor: 5.000

9.  Potential of gene therapy as a treatment for heart failure.

Authors:  Roger J Hajjar
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

10.  REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma.

Authors:  Lucia Di Marcotullio; Elisabetta Ferretti; Enrico De Smaele; Beatrice Argenti; Claudia Mincione; Francesca Zazzeroni; Rita Gallo; Laura Masuelli; Maddalena Napolitano; Marella Maroder; Andrea Modesti; Felice Giangaspero; Isabella Screpanti; Edoardo Alesse; Alberto Gulino
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.